Last updated: April 23, 2026
What does CN117597106 cover?
CN117597106 is a China patent application/patent document that targets pharmaceutical use tied to a defined chemical entity and its preparation/utility within specific therapeutic context. The document is published under China’s patent system and appears within the broader class of small-molecule medicinal products and associated compositions/use claims, where scope is typically defined by (i) the claimed compound or intermediate, (ii) formulation/composition parameters, (iii) method-of-treatment indications, and (iv) supporting experimental evidence.
Scope focus in Chinese filings of this family type
Based on the way CN publications are drafted in this category, the practical scope you should map is:
- Compound scope: exact chemical structure(s) and any Markush-style alternatives if present.
- Composition/formulation scope: dosage forms, excipients, and concentration ranges if claimed.
- Method-of-use scope: therapeutic indication and patient/condition definitions if claimed.
- Manufacturing scope: process steps and intermediates if process claims are included.
What are the key claim layers to map?
Chinese drug patents in this format usually split into three claim layers: (1) composition/compound, (2) use/method, and (3) preparation/process. For CN117597106, the operative landscape mapping for freedom-to-operate and validity work should be built around these layers:
1) Compound (or specific chemical entity) protection
Your landscape model should treat compound claims as the center of gravity. Look for:
- Independent claim(s) listing the compound by structure and/or formula.
- Dependent claims that constrain substitution patterns, stereochemistry, salt forms, or crystal forms.
- Definition claims that broaden via “including” language or Markush lists (if used).
2) Pharmaceutical composition claims
Map for:
- Dosage form (tablet, capsule, injection, granule, etc.).
- Excipients and ratios (if numerically specified).
- Physicochemical constraints (particle size, solubility enhancement, pH range, etc.) that tighten scope and reduce design-around risk.
3) Therapeutic use / method-of-treatment claims
Map for:
- Indication language (disease/condition terms in Chinese).
- Treatment regimen parameters (dose, frequency, duration) if present.
- Patient subgroup definitions (adult/pediatric, refractory, biomarker-positive) if used.
4) Process and intermediate claims (if present)
Process claims determine manufacturing freedom. Map for:
- Step-by-step synthesis with defined reagents and conditions.
- Intermediates that can act as blocking points for contract manufacturing and API supply.
- Purification/crystallization conditions that can create enforceable manufacturing bottlenecks.
How should the scope be read for enforceability in China?
Chinese claim interpretation in enforcement often turns on:
- Exactness of chemical definitions: structure and functional group definitions.
- Limitations in dependent claims: dependent constraints can matter for infringement if the dependent features are used.
- Clarity of therapeutic indication: method-of-use claims are enforced when a product is shown to be administered for the claimed indication under a covered regimen.
- Salt/polymorph/crystal form specificity: if the claims recite specific forms, those are harder to design around using different forms without entering equivalents.
What is the patent landscape around CN117597106 in China?
CN117597106 sits inside a China landscape shaped by three overlapping systems:
- CNP (China National Patent) families covering compounds and uses.
- Drug registration (NMPA) protection that can create practical market exclusivity even when patents are narrow.
- International families (PCT/EP/US) that commonly feed the Chinese prosecution.
Landscape mapping framework (actionable)
Use this structure to build a blocking vs non-blocking map:
A. Same-entity families in China
- Identify other CN publications/patents that claim the same compound or close analogs.
- Prioritize:
- Earlier filing dates (priority chain)
- Same therapeutic indication (use claims)
- Same salt/polymorph/form (form-specific claims)
B. Upstream chemistry families
- Find process and intermediate patents that can overlap with CN117597106 compound production.
- For enforcement risk, process and intermediate claims can be as important as compound claims if they cover key steps.
C. Downstream formulation and method families
- Check for later CN filings that claim:
- specific dosage forms
- specific dosing regimens
- combination therapy if CN117597106 covers monotherapy
D. Competitive design-around space
- Identify close alternatives that differ by:
- substitution pattern on the scaffold
- stereochemistry
- salt form
- polymorph
- excipient system
- indication wording
What do claim breadth signals imply for market exclusivity?
In this category, breadth signals typically come from:
- whether the claim uses structure-only coverage (broader) versus form-specific or exemplar-only language (narrower);
- whether dependent claims lock into a single dose or narrow range;
- whether therapeutic language is generic disease wording or limited to specific patient conditions.
For practical business use:
- Broader compound + generic use claims tend to block multiple generics early.
- Narrow form/regimen claims tend to allow partial carve-outs but can still block the exact commercial product profile.
How to stress-test scope against common generic pathways
When you model design-around and generic entry, stress tests should focus on how a competitor can avoid each claim layer:
If compound claims are broad
Typical workarounds (if not blocked by dependent claims) include:
- alternative salt form
- alternative polymorph/crystal form
- stereoisomer selection
- close analog substitution
If composition claims dominate
Competitors can often change:
- excipient systems
- dosage form type
- concentration and pH
- manufacturing constraints that affect solubility/stability
If method-of-treatment claims dominate
Competitors can sometimes:
- change indication labeling
- restrict to off-claim regimens
- avoid the exact patient subgroup described in the claims
If process claims dominate
Competitors often:
- change synthesis route
- substitute reagents/conditions
- isolate different intermediates (if not covered)
Key claim-precision checkpoints for infringement and validity
Use these checkpoints to decide whether CN117597106 behaves like a “blocking” patent:
- Compound definition: Is it limited to a single structure or a Markush range?
- Salt/polymorph: Are forms individually claimed?
- Use claim wording: Is the indication broad (disease class) or narrow (specific clinical condition)?
- Dose/regimen constraints: Are numeric regimens required?
- Examples vs claims: Are example embodiments used to narrow interpretation?
Key patent landscape scenarios for CN117597106
Build three scenarios around likely enforcement posture:
Scenario 1: Compound claims are independent and broad
- High blocking power against generics that use the same API entity.
- Expect additional filings that tie into specific forms and formulations.
Scenario 2: Compound claims are narrow; use claims broaden utility
- Blocks the exact covered medical use more than the molecule per se.
- A competitor can still enter with a different indication or labeling strategy.
Scenario 3: Formulation and regimen claims carry the weight
- Protects a marketed dosage profile more than the API.
- Competitors may enter with an alternative formulation or dosing regimen.
How long does CN117597106 protection typically last (China)?
Standard China patent term for invention patents is 20 years from the filing date (subject to adjustments). For enforcement planning, map:
- priority date
- national filing date
- any patent term adjustment/extension events
- expiration risk for different claim sets (compound vs use vs process).
Key Takeaways
- CN117597106 is a China drug patent that should be mapped by compound scope, composition/formulation scope, and method-of-treatment scope; process/intermediate claims can also materially affect freedom-to-operate.
- The enforceability and design-around space hinge on how chemical definitions and therapeutic indication language are drafted, especially salt/polymorph and dose/regimen constraints.
- Your landscape should identify same-entity CN families, upstream process/intermediate patents, and downstream formulation/use filings, then stress-test generic entry paths against each claim layer.
- Treat CN117597106 as potentially blocking or carve-outable depending on whether independent claims are broad and whether dependent claims add narrow constraints.
FAQs
1) What determines whether CN117597106 blocks generic entry in China?
Independent claim breadth on the API entity and whether use/composition claims tightly constrain the commercial product profile.
2) How can a competitor design around CN117597106?
By changing elements that align with claim limitations, typically salt/polymorph, stereochemistry, formulation/dosage form, indication wording, or regimen; process workarounds depend on whether synthesis steps/intermediates are claimed.
3) Which claim layer is most important for enforcement risk?
Usually the compound (or API definition) layer. If that is narrow, method-of-use and form/regimen claims can become the primary blocking vector.
4) How do related CN filings affect the CN117597106 landscape?
Same-entity or same-therapeutic filings can stack and create cumulative blocking risk; upstream process patents can block API supply even when compound scope is narrow.
5) What timeline matters most for market entry planning?
Map the patent’s priority/filing timeline and standard 20-year term from filing, then layer in practical registration and exclusivity effects where applicable.
References
[1] China National Intellectual Property Administration (CNIPA). China patent publication system and legal framework for invention patent term and claim structure.
